AR038700A1 - Anticuerpos monoclonales anti-tenascina humana - Google Patents
Anticuerpos monoclonales anti-tenascina humanaInfo
- Publication number
- AR038700A1 AR038700A1 ARP030100622A ARP030100622A AR038700A1 AR 038700 A1 AR038700 A1 AR 038700A1 AR P030100622 A ARP030100622 A AR P030100622A AR P030100622 A ARP030100622 A AR P030100622A AR 038700 A1 AR038700 A1 AR 038700A1
- Authority
- AR
- Argentina
- Prior art keywords
- human anti
- tenascin
- seq
- monoclonal antibody
- tenascine
- Prior art date
Links
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 101000666340 Homo sapiens Tenascin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000057345 human TNC Human genes 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 230000002797 proteolythic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35929902P | 2002-02-26 | 2002-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038700A1 true AR038700A1 (es) | 2005-01-26 |
Family
ID=27766061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100622A AR038700A1 (es) | 2002-02-26 | 2003-02-26 | Anticuerpos monoclonales anti-tenascina humana |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7438908B2 (enExample) |
| EP (1) | EP1478667B1 (enExample) |
| JP (1) | JP4488746B2 (enExample) |
| KR (1) | KR101048894B1 (enExample) |
| CN (1) | CN1317303C (enExample) |
| AR (1) | AR038700A1 (enExample) |
| AT (1) | ATE480564T1 (enExample) |
| AU (1) | AU2003215900B2 (enExample) |
| BR (1) | BR0307994A (enExample) |
| CA (1) | CA2475395C (enExample) |
| CY (1) | CY1111108T1 (enExample) |
| DE (1) | DE60334076D1 (enExample) |
| DK (1) | DK1478667T3 (enExample) |
| ES (1) | ES2352180T3 (enExample) |
| MX (1) | MXPA04008216A (enExample) |
| PL (1) | PL213216B1 (enExample) |
| PT (1) | PT1478667E (enExample) |
| SI (1) | SI1478667T1 (enExample) |
| WO (1) | WO2003072608A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20040105A1 (it) * | 2004-02-27 | 2004-05-27 | Tecnogen Scpa | Anticorpo monoclonale antitenascina umana. |
| WO2008019326A2 (en) * | 2006-08-04 | 2008-02-14 | Novartis Ag | Ephb3-specific antibody and uses thereof |
| EP2235536A4 (en) | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2-DIAGNOSTIC PROCEDURE |
| FR2930036B1 (fr) * | 2008-04-11 | 2010-05-07 | Assist Publ Hopitaux De Paris | Procede de diagnostic d'une hypertension arterielle pulmonaire. |
| EP2313435A4 (en) * | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS |
| ES2637411T3 (es) | 2008-12-01 | 2017-10-13 | Laboratory Corporation Of America Holdings | Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95 |
| JP5746051B2 (ja) * | 2009-01-15 | 2015-07-08 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | Ｈｅｒ−３の測定による患者の反応を判定する方法 |
| JP2012515353A (ja) * | 2009-01-15 | 2012-07-05 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | Ｈｅｒ−２発現の測定による患者の反応を判定する方法 |
| US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| US20120269814A1 (en) * | 2009-11-10 | 2012-10-25 | Amgen Inc. | Anti-c mpl antibodies |
| WO2012051498A2 (en) * | 2010-10-15 | 2012-04-19 | The Board Of Regents Of The University Of Texas System | Antibodies that bind amyloid oligomers |
| US9032525B2 (en) | 2011-03-29 | 2015-05-12 | Mcafee, Inc. | System and method for below-operating system trapping of driver filter attachment |
| US8925089B2 (en) | 2011-03-29 | 2014-12-30 | Mcafee, Inc. | System and method for below-operating system modification of malicious code on an electronic device |
| US9087199B2 (en) | 2011-03-31 | 2015-07-21 | Mcafee, Inc. | System and method for providing a secured operating system execution environment |
| US9317690B2 (en) | 2011-03-28 | 2016-04-19 | Mcafee, Inc. | System and method for firmware based anti-malware security |
| US8959638B2 (en) | 2011-03-29 | 2015-02-17 | Mcafee, Inc. | System and method for below-operating system trapping and securing of interdriver communication |
| US9262246B2 (en) | 2011-03-31 | 2016-02-16 | Mcafee, Inc. | System and method for securing memory and storage of an electronic device with a below-operating system security agent |
| US8813227B2 (en) | 2011-03-29 | 2014-08-19 | Mcafee, Inc. | System and method for below-operating system regulation and control of self-modifying code |
| US9038176B2 (en) | 2011-03-31 | 2015-05-19 | Mcafee, Inc. | System and method for below-operating system trapping and securing loading of code into memory |
| US8966624B2 (en) | 2011-03-31 | 2015-02-24 | Mcafee, Inc. | System and method for securing an input/output path of an application against malware with a below-operating system security agent |
| US8966629B2 (en) | 2011-03-31 | 2015-02-24 | Mcafee, Inc. | System and method for below-operating system trapping of driver loading and unloading |
| US8863283B2 (en) | 2011-03-31 | 2014-10-14 | Mcafee, Inc. | System and method for securing access to system calls |
| US9255595B2 (en) * | 2011-04-29 | 2016-02-09 | Bae Systems Information And Electronic Systems Integration Inc. | Optical dome bezel |
| EP2791686B1 (en) * | 2011-12-12 | 2017-02-15 | Oxford University Innovation Limited | Tenascin-c and use thereof in rheumatoid arthritis |
| JP6463331B2 (ja) | 2013-03-15 | 2019-01-30 | イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー | 抗ヘプシジン抗体およびその使用 |
| GB201414021D0 (en) * | 2014-08-07 | 2014-09-24 | Nascient Ltd | Biological materials and uses thereof |
| AU2015321462B2 (en) | 2014-09-22 | 2020-04-30 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| GB201602413D0 (en) * | 2016-02-10 | 2016-03-23 | Nascient Ltd | Method |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4687732A (en) | 1983-06-10 | 1987-08-18 | Yale University | Visualization polymers and their application to diagnostic medicine |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994021293A1 (en) * | 1993-03-19 | 1994-09-29 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| US5482698A (en) | 1993-04-22 | 1996-01-09 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin polymer conjugates |
| CA2163976C (en) | 1993-05-28 | 2010-06-29 | Didier J. Leturcq | Methods and compositions for inhibiting cd14 mediated cell activation |
| US6335014B1 (en) | 1998-06-17 | 2002-01-01 | The Institute Of Physical And Chemical Research | Medicament for suppressing cancer metastasis |
| ITRM20020128A1 (it) | 2002-03-08 | 2003-09-08 | Sigma Tau Ind Farmaceuti | Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting". |
-
2003
- 2003-02-20 EP EP03743010A patent/EP1478667B1/en not_active Expired - Lifetime
- 2003-02-20 BR BR0307994-5A patent/BR0307994A/pt not_active IP Right Cessation
- 2003-02-20 KR KR1020047013068A patent/KR101048894B1/ko not_active Expired - Fee Related
- 2003-02-20 CN CNB038046342A patent/CN1317303C/zh not_active Expired - Fee Related
- 2003-02-20 AT AT03743010T patent/ATE480564T1/de active
- 2003-02-20 JP JP2003571313A patent/JP4488746B2/ja not_active Expired - Lifetime
- 2003-02-20 MX MXPA04008216A patent/MXPA04008216A/es active IP Right Grant
- 2003-02-20 WO PCT/IT2003/000098 patent/WO2003072608A1/en not_active Ceased
- 2003-02-20 CA CA2475395A patent/CA2475395C/en not_active Expired - Fee Related
- 2003-02-20 DE DE60334076T patent/DE60334076D1/de not_active Expired - Lifetime
- 2003-02-20 PL PL372803A patent/PL213216B1/pl unknown
- 2003-02-20 SI SI200331899T patent/SI1478667T1/sl unknown
- 2003-02-20 AU AU2003215900A patent/AU2003215900B2/en not_active Ceased
- 2003-02-20 ES ES03743010T patent/ES2352180T3/es not_active Expired - Lifetime
- 2003-02-20 PT PT03743010T patent/PT1478667E/pt unknown
- 2003-02-20 US US10/505,747 patent/US7438908B2/en not_active Expired - Lifetime
- 2003-02-20 DK DK03743010.5T patent/DK1478667T3/da active
- 2003-02-25 US US10/372,719 patent/US20040005643A1/en not_active Abandoned
- 2003-02-26 AR ARP030100622A patent/AR038700A1/es not_active Application Discontinuation
-
2008
- 2008-09-17 US US12/232,431 patent/US8048417B2/en not_active Expired - Fee Related
-
2010
- 2010-12-01 CY CY20101101107T patent/CY1111108T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7438908B2 (en) | 2008-10-21 |
| EP1478667A1 (en) | 2004-11-24 |
| CA2475395C (en) | 2011-08-02 |
| ES2352180T3 (es) | 2011-02-16 |
| CN1639192A (zh) | 2005-07-13 |
| SI1478667T1 (sl) | 2010-12-31 |
| BR0307994A (pt) | 2004-12-07 |
| JP2005534615A (ja) | 2005-11-17 |
| US8048417B2 (en) | 2011-11-01 |
| DE60334076D1 (de) | 2010-10-21 |
| EP1478667B1 (en) | 2010-09-08 |
| US20110020219A1 (en) | 2011-01-27 |
| PL213216B1 (pl) | 2013-01-31 |
| ATE480564T1 (de) | 2010-09-15 |
| AU2003215900A1 (en) | 2003-09-09 |
| CY1111108T1 (el) | 2015-06-11 |
| WO2003072608A1 (en) | 2003-09-04 |
| KR101048894B1 (ko) | 2011-07-13 |
| PT1478667E (pt) | 2010-12-09 |
| JP4488746B2 (ja) | 2010-06-23 |
| HK1078589A1 (en) | 2006-03-17 |
| DK1478667T3 (da) | 2010-12-20 |
| CN1317303C (zh) | 2007-05-23 |
| AU2003215900B2 (en) | 2008-09-25 |
| US20040005643A1 (en) | 2004-01-08 |
| KR20040086426A (ko) | 2004-10-08 |
| MXPA04008216A (es) | 2004-11-26 |
| US20050106145A1 (en) | 2005-05-19 |
| CA2475395A1 (en) | 2003-09-04 |
| PL372803A1 (en) | 2005-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038700A1 (es) | Anticuerpos monoclonales anti-tenascina humana | |
| PE20050727A1 (es) | Anticuerpos dirigidos a c-met | |
| ES2161751T3 (es) | Anticuerpo monoclonal que se une especificamente al endotelio vascular tumoral y usos del mismo. | |
| ES2564252T3 (es) | Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos | |
| CY1118709T1 (el) | Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf | |
| ES2653664T3 (es) | Generación y caracterización de anticuerpos terapéuticos obtenidos mediante HuCal GOLD completamente humanos específicos de CD38 humano | |
| HRP20090517T1 (hr) | Protutijela na interleukin-10 | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| CO4480111A1 (es) | Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes | |
| AR016243A1 (es) | Un anticuerpo proteico que tiene las regiones determinantes de la complementariedad del anticuerpo monoclonal f19 y que se fija especificamente a laproteina de activacion de fibroblastos; el empleo de dicho anticuerpo proteico para el tratamiento del cancer, para representar en imagenes fibroblastos | |
| CO6231040A2 (es) | Moleculas y metodos para modular la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) | |
| ES2572231T3 (es) | Anticuerpos monoclonales anti-IL-21 humana | |
| AR033978A1 (es) | Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas | |
| CO6231038A2 (es) | Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos | |
| ATE263189T1 (de) | Antikörper gegen menschliches prostatspezifisches drüsenkallikrein | |
| ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
| CY1116913T1 (el) | Τροποποιημενα κλασματα fab αντισωματων | |
| ES2621874T3 (es) | Anticuerpos para MUC16 y métodos de uso de los mismos | |
| PE20050712A1 (es) | Anticuerpos rg1 | |
| ES2165851T3 (es) | Proteinas multivalentes que se unen a antigenos. | |
| PE20071055A1 (es) | Anticuerpos anti mn | |
| DE69932812D1 (de) | Epitope in der viralen hüllproteine und spezifische antikörper gegen diese epitope: verwendung für die detektion von hcv viralantigene im empfängergewebe | |
| PE20232050A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| ATE140486T1 (de) | Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung | |
| ES2123558T3 (es) | Antigenos peptidicos del vhc y procedimiento para la determinacion del vhc. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |